Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Jubilant Pharmova Ltd - 530019 - Investment Of US$92 Million By Jubilant Pharma Limited, A Wholly-Owned Subsidiary Of The Company

 Dear Sirs, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to investment of US$92 million by Jubilant Pharma Limited, a wholly-owned subsidiary of the Company for expansion of sterile injectable manufacturing capacity at the Spokane site in Washington, US. We request you to take the same on record.
31-05-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Schedule Of Investor Conference Call For Jubilant Pharmova Limited - Audited Financial Results For The Year Ended March 31, 2021

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on June 4, 2021 after submission of the financial results for the quarter and year ended March 31, 2021 to the Stock Exchanges. Details of the Conference Call are attached.
28-05-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Board Meeting Intimation for 1. Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2021; And 2. Recommendation Of Dividend For The Financial Year Ended March 31, 2021.

 Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/06/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, June 4, 2021, to inter-alia consider: 1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2021; and 2. Recommendation of Dividend for the Financial Year ended March 31, 2021.
28-05-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that India Ratings and Research has upgraded Long Term Issuer Rating to 'IND AA+' from 'IND AA' while resolving the Rating Watch Evolving (RWE) and has simultaneously withdrawn it. The Outlook is stable.
27-05-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Intimation Of Transfer Of Shares In Physical Mode In Terms Of SEBI Circular No. SEBI/ HO/MIRSD/DOS3/CIR/P/2018/139 Dated November 6, 2018

 Pursuant to Clause 2(c)(iii)(5) of the Securities and Exchange Board of India Circular No. SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 dated November 6, 2018. We wish to inform you that a request for transfer of shares in physical mode has been approved by the Company. The details of transfer are given in the attachment. The aforesaid shares have been transferred to the Investor Education and Protection Fund ('IEPF') pursuant to the IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016. The said transferee can make an application to the IEPF for release of shares after expiry of lock-in period of 6 months from the date of transfer. The above information will also be made available on the Company's website www.jubilantpharmova.com. This is for your information and record.
25-05-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Jubilant Pharma Wins Over Bracco'S Legal Appeals In The United States Court Of Appeals

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to favorable ruling received by Jubilant Pharma Limited, Singapore, a subsidiary of the Company from the United States Court of Appeals regarding Jubilant's RUBY-FILL(r) Generator and RUBY Rubidium Elution System(tm).
08-05-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Intimation Pursuant To Regulation 60(2) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Record Date

 Transfer of Non-convertible Debentures of Rs. 100 Crore issued by the Company to Jubilant Ingrevia Limited pursuant to the Composite Scheme of Arrangement - ISIN No. INE700A07089
07-05-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that CRISIL Ratings has removed Long Term Bank Facilities and Non-Convertible Debentures of the Company from ''Rating Watch with Developing Implications'' and has assigned a 'Positive' outlook for the long-term rating. CRISIL Ratings has also withdrawn the rating on the bank facilities on receipt of a ''No Objection Certificate' from the banker and on debt instruments of the Company, as the bank facilities and debt instruments have been transferred to Jubilant Ingrevia Limited, post demerger of the Life Science Ingredients Business of the Company. The rating withdrawal is based on the Company's request and in line with CRISIL Rating's policy on withdrawal of ratings. The instrument-wise ratings are given in the attached letter.
07-05-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Format of the Annual Disclosure to be made by an entity identified as a Large Corporate

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Compay Jubilant Pharmova Ltd 2 CIN L24116UP1978PLC004624 3 Report filed for FY 2021 Details of the borrowings (all figures in Rs crore) 4 Incremental borrowing done in FY(a) 100 5 Mandatory borrowing to be done through issuance of debt securities(b) = (25% of a) 25 6 Actual borrowings done through debt securities in FY(c) 100 7 Shortfall in the mandatory borrowing through debt securities, if any (d) = (b) - (c) { If the calculated value is zero or negative, write 'nil'} 0 8 Reasons for shortfall, if any, in mandatory borrowings through debt securities Not Applicable Name of the Company Secretary :-Rajiv ShahDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Arun Kumar Sharma Designation : -Chief Financial Officer Date: 29/04/2021
29-04-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayJubilant Pharmova Ltd 2CINL24116UP1978PLC004624 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Rajiv Shah Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Arun Kumar Sharma Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
29-04-2021
Next Page
Close

Let's Open Free Demat Account